Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3476
Vitamin Cottage Natural Grocers
NGVC
$648M
| $886K | ﹤0.01% |
35,360
-22,889
| -39% | -$733K |
|
3477
PUT
Doximity
DOCS
$4.57B
| $886K | ﹤0.01% |
+20,000
| New | +$1.12M |
|
|
HTFL
3478
Heartflow Inc
HTFL
$2.53B
| $884K | ﹤0.01% |
30,336
+13,618
| +81% | +$438K |
|
3479
PUT
Live Nation Entertainment
LYV
$43.3B
| $884K | ﹤0.01% |
6,200
| – | – |
|
3480
Pacific Biosciences
PACB
$361M
| $883K | ﹤0.01% |
472,108
+72,201
| +18% | +$139K |
|
3481
Tredegar Corp
TG
$275M
| $882K | ﹤0.01% |
122,808
+9,435
| +8% | +$71.5K |
|
3482
CALL
Workday
WDAY
$46B
| $881K | ﹤0.01% |
4,100
| – | – |
|
3483
Allogene Therapeutics
ALLO
$697M
| $880K | ﹤0.01% |
642,687
+43,690
| +7% | +$57.6K |
|
3484
Cracker Barrel
CBRL
$1.31B
| $880K | ﹤0.01% |
34,656
+2,378
| +7% | +$76.1K |
|
3485
FerroAtlántica
GSM
$820M
| $879K | ﹤0.01% |
189,524
+21,333
| +13% | +$98.5K |
|
3486
Climb Global Solutions
CLMB
$527M
| $879K | ﹤0.01% |
34,212
+3,080
| +10% | +$89.4K |
|
3487
Ranger Energy Services
RNGR
$402M
| $879K | ﹤0.01% |
62,854
+18,055
| +40% | +$245K |
|
|
GOOD
3488
Gladstone Commercial Corp
GOOD
$637M
| $877K | ﹤0.01% |
82,229
+7,109
| +9% | +$79K |
|
3489
Evolent Health
EVH
$500M
| $877K | ﹤0.01% |
219,141
+14,506
| +7% | +$80.6K |
|
3490
Pearson
PSO
$9.72B
| $875K | ﹤0.01% |
+62,304
| New | +$862K |
|
3491
BayCom
BCML
$343M
| $875K | ﹤0.01% |
29,748
+1,320
| +5% | +$38.1K |
|
|
EU
3492
enCore Energy
EU
$227M
| $873K | ﹤0.01% |
352,127
+53,434
| +18% | +$153K |
|
3493
Energy Vault
NRGV
$694M
| $872K | ﹤0.01% |
189,121
+189,119
| +9,455,950% | +$723K |
|
3494
Eton Pharmaceutcials
ETON
$1.15B
| $870K | ﹤0.01% |
51,448
+14,642
| +40% | +$258K |
|
3495
Evolus
EOLS
$543M
| $869K | ﹤0.01% |
130,738
+24,845
| +23% | +$168K |
|
3496
Five Star Bancorp
FSBC
$1.16B
| $868K | ﹤0.01% |
24,252
+1,528
| +7% | +$53K |
|
3497
Atea Pharmaceuticals
AVIR
$411M
| $867K | ﹤0.01% |
242,990
+1,526
| +0.6% | +$4.85K |
|
3498
Enanta Pharmaceuticals
ENTA
$399M
| $867K | ﹤0.01% |
54,989
+13,368
| +32% | +$170K |
|
3499
Liberty Media Series A
FWONA
$23.8B
| $861K | ﹤0.01% |
9,636
+101
| +1% | +$9.06K |
|
3500
PUT
Sarepta Therapeutics
SRPT
$1.94B
| $861K | ﹤0.01% |
40,000
-30,000
| -43% | -$632K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.